Figures computed from official regulatory filings — .
Analysttarget 141.4 USD (+224%) · consensus 4.58/5 · 10 buy · 2 hold · 0 sell
Ownershipinsiders 0.38% · institutions 107.69% · short 18.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for NEKTAR THERAPEUTICS only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
14 buys1,259 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ajer Jeffrey Robert | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brainard Diana | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CHESS ROBERT | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WHITFIELD ROY A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GREER R SCOTTtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CHESS ROBERT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ajer Jeffrey Robert | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WHITFIELD ROY A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Brainard Diana | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GREER R SCOTTtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zalevsky Jonathan | Sell | $13.4K | SEC |
| ROBIN HOWARD W | Sell | $30.1K | SEC |
| ROBIN HOWARD W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zalevsky Jonathan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zalevsky Jonathan | Sell | $397.7K | Unusual size | SEC |
| ROBIN HOWARD W | Sell | $285.2K | Unusual size | SEC |
| ROBIN HOWARD W | Sell | $277.4K | Unusual size | SEC |
| ROBIN HOWARD W | Sell | $334.5K | Unusual size | SEC |
| ROBIN HOWARD W | Sell | $318K | Unusual size | SEC |
| Zalevsky Jonathan | Sell | $336.2K | Unusual size | SEC |
| Zalevsky Jonathan | Sell | $13K | SEC |
| ROBIN HOWARD W | Sell | $29.1K | SEC |
| Zalevsky Jonathan | Sell | $13.1K | SEC |
| ROBIN HOWARD W | Sell | $30.9K | SEC |
| Zalevsky Jonathan | Sell | $137.9K | SEC |